Yiming Meng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yiming Meng has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Jing Sun
Department of Biobank, Liaoning Cancer Hospital and Institute, Cancer Hospital of Dalian University of Technology
17 shared publicationsGuirong Zhang
Department of Central Laboratory, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, Shenyang, China
13 shared publicationsYushu Ma
Department of Central Laboratory, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute
5 shared publicationsCuicui Kong
Department of Central Laboratory, Liaoning Cancer Hospital and Institute, Cancer Hospital of Dalian University of Technology
4 shared publicationsHaozhe Piao
Department of Central Laboratory Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute Dadong district Shenyang China
3 shared publications- Haozhe Piao
Department of Central Laboratory, Liaoning Cancer Hospital and Institute, Cancer Hospital of China Medical University, Shenyang, China
3 shared publications
Latest Publications
- Open Access
- 9 September 2026
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 14, 1924917
Editorial: Bidirectional gut-brain interactions in modulating central nervous system diseases
The relationship between the gastrointestinal tract and the central nervous system (CNS) has undergone a profound conceptual evolution over the past two decades. Once considered a largely unidirectional axis in which the brain governed gut function, this relationship is now recognized as a sophisticated, bidirectional communication network integrating neural, endocrine, immune, and microbial signals. The gut microbiota-comprising trillions of bacteria, fungi, viruses, and archaea-encodes a metabolic repertoire that rivals the human genome in complexity, producing neuroactive metabolites, modulating systemic immune tone, and influencing blood-brain barrier integrity. Simultaneously, CNS perturbations ranging from acute injury to chronic psychiatric illness reshape microbial composition, intestinal motility, and epithelial barrier function. This reciprocal vulnerability has catalyzed enormous research interest, not only in understanding disease mechanisms but in identifying the gut as an accessible and modifiable therapeutic target.The ten contributions assembled here span cerebrovascular, neuropsychiatric, neuro-oncological, iatrogenic, and extra-cranial disease contexts. Collectively, they delineate four converging themes: (i) microbial dysbiosis as both a consequence and a driver of CNS pathology; (ii) the centrality of barrier integrity in shaping disease trajectory; (iii) microbiotaderived metabolites as bona fide neuroactive molecules; and (iv) the stillincomplete translation of these insights into standardized therapeutics.Stroke represents one of the most intensively studied contexts for gut-brain interaction, and two contributions in this Topic address complementary dimensions of this relationship. Jia et al. reported that the large intestine functions not merely as a digestive organ but as a critical immunological and neuroendocrine interface in ischemic stroke, detailing how intestinal epithelial cells, barrier integrity, and the enteric neural network are disrupted by cerebrovascular injury while simultaneously feeding back to modulate neuroinflammatory cascades in the ischemic brain (Jia et al., 2026). Extending this mechanistic foundation to therapeutic translation, Wang et al. systematically reviewed gut microbiota-based strategies for stroke prevention and treatment, evaluating the evidence for probiotics, prebiotics, fecal microbiota transplantation (FMT), and dietary interventions, while underscoring persistent challenges including individual microbiome heterogeneity, efficacy stability, and long-term safety (Wang et al., 2025). A particularly important neuropsychiatric sequela of stroke is addressed by Jiang et al., who proposed a novel microbiota-immune-barrier axis to explain post-stroke depression (PSD) (Jiang et al., 2025). Their review argues that ischemic stroke-induced gut dysbiosis compromises both intestinal and blood-brain barrier integrity through dysregulated immune signaling, thereby precipitating or amplifying depressive symptoms in more than one-third of ischemic stroke survivors -a population that remains substantially undertreated in clinical practice.Spinal cord injury (SCI) presents a distinct but mechanistically related challenge. Yin et al (Yin et al., 2026). provided a comprehensive bench-tobedside synthesis of the emerging "gut microbiota-gut-spinal cord" axis, GABA receptors and transporters operate at multiple levels-CNS circuits, the enteric nervous system, and gut epithelium-and that gut microbiota-derived GABA production directly links microbial composition to inhibitory neurotransmitter tone within the microbiota-gut-brain axis (Lambiase et al., 2025). Altered GABA signaling and reduced GABA levels, particularly in diarrhea-predominant IBS subtypes, suggest that GABAergic pathways represent both a disease mechanism and a therapeutic target, though the authors note that clinical evidence for GABA-based interventions remains limited and largely preclinical. Addressing the comorbidity of depression and constipation through a translational lens, Xu et al. reported that the traditional Chinese medicine formula Liqi Yangyin (LQYY) ameliorates chronic unpredictable mild stress (CUMS)-induced behavioral changes and intestinal dysmotility through ACE/FFAR2-mediated modulation of the microbiota-gutbrain axis, with downstream effects including reduced microglial neuroinflammation, restored intestinal and blood-brain barrier integrity, and enhanced colonic serotonin secretion-mechanistic findings subsequently confirmed in BV-2 cell culture models (Xu et al., 2025).Expanding beyond classical gut-brain dyads, several contributions introduce novel axis frameworks with broad clinical implications. Zhang et al. explored the interaction between gut microbiota and anesthesia through the lens of the gut-brain-liver axis, revealing that anesthetic agents reshape microbial composition by disrupting intestinal barrier function, suppressing beneficial bacterial populations, and inducing bile acid metabolism dysregulation-changes that in turn impair hepatic drug-metabolizing enzyme activity and sustain neuroinflammatory cycles with direct perioperative safety consequences (Zhang et al., 2025). Song et al. proposed a brain-gut-prostate axis in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), integrating microbiome-derived metabolite signaling (including SCFAs and thyrotropinreleasing hormone), neuroendocrine pathways, and Th17/Treg immune imbalance to construct a theoretical framework that transcends conventional localized anti-inflammatory approaches and offers multi-dimensional therapeutic strategies for this clinically refractory condition (Song et al., 2025). Zhai et al. examined Drug-induced brain injury (DIBI) through the gut-brain axis, demonstrating that antibiotic, antineoplastic, and psychoactive drug exposures promote microbial dysbiosis, bacterial translocation, and systemic inflammation that ultimately compromise blood-brain barrier...
- 9 September 2026
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 14, 1924917
Open AccessEditorial: Bidirectional gut-brain interactions in modulating central nervous system diseases
The relationship between the gastrointestinal tract and the central nervous system (CNS) has undergone a profound conceptual evolution over the past two decades. Once considered a largely unidirectional axis in which the brain governed gut function, this relationship is now recognized as a sophisticated, bidirectional communication network integrating neural, endocrine, immune, and microbial signals. The gut microbiota-comprising trillions of bacteria, fungi, viruses, and archaea-encodes a metabolic repertoire that rivals the human genome in complexity, producing neuroactive metabolites, modulating systemic immune tone, and influencing blood-brain barrier integrity. Simultaneously, CNS perturbations ranging from acute injury to chronic psychiatric illness reshape microbial composition, intestinal motility, and epithelial barrier function. This reciprocal vulnerability has catalyzed enormous research interest, not only in understanding disease mechanisms but in identifying the gut as an accessible and modifiable therapeutic target.The ten contributions assembled here span cerebrovascular, neuropsychiatric, neuro-oncological, iatrogenic, and extra-cranial disease contexts. Collectively, they delineate four converging themes: (i) microbial dysbiosis as both a consequence and a driver of CNS pathology; (ii) the centrality of barrier integrity in shaping disease trajectory; (iii) microbiotaderived metabolites as bona fide neuroactive molecules; and (iv) the stillincomplete translation of these insights into standardized therapeutics.Stroke represents one of the most intensively studied contexts for gut-brain interaction, and two contributions in this Topic address complementary dimensions of this relationship. Jia et al. reported that the large intestine functions not merely as a digestive organ but as a critical immunological and neuroendocrine interface in ischemic stroke, detailing how intestinal epithelial cells, barrier integrity, and the enteric neural network are disrupted by cerebrovascular injury while simultaneously feeding back to modulate neuroinflammatory cascades in the ischemic brain (Jia et al., 2026). Extending this mechanistic foundation to therapeutic translation, Wang et al. systematically reviewed gut microbiota-based strategies for stroke prevention and treatment, evaluating the evidence for probiotics, prebiotics, fecal microbiota transplantation (FMT), and dietary interventions, while underscoring persistent challenges including individual microbiome heterogeneity, efficacy stability, and long-term safety (Wang et al., 2025). A particularly important neuropsychiatric sequela of stroke is addressed by Jiang et al., who proposed a novel microbiota-immune-barrier axis to explain post-stroke depression (PSD) (Jiang et al., 2025). Their review argues that ischemic stroke-induced gut dysbiosis compromises both intestinal and blood-brain barrier integrity through dysregulated immune signaling, thereby precipitating or amplifying depressive symptoms in more than one-third of ischemic stroke survivors -a population that remains substantially undertreated in clinical practice.Spinal cord injury (SCI) presents a distinct but mechanistically related challenge. Yin et al (Yin et al., 2026). provided a comprehensive bench-tobedside synthesis of the emerging "gut microbiota-gut-spinal cord" axis, GABA receptors and transporters operate at multiple levels-CNS circuits, the enteric nervous system, and gut epithelium-and that gut microbiota-derived GABA production directly links microbial composition to inhibitory neurotransmitter tone within the microbiota-gut-brain axis (Lambiase et al., 2025). Altered GABA signaling and reduced GABA levels, particularly in diarrhea-predominant IBS subtypes, suggest that GABAergic pathways represent both a disease mechanism and a therapeutic target, though the authors note that clinical evidence for GABA-based interventions remains limited and largely preclinical. Addressing the comorbidity of depression and constipation through a translational lens, Xu et al. reported that the traditional Chinese medicine formula Liqi Yangyin (LQYY) ameliorates chronic unpredictable mild stress (CUMS)-induced behavioral changes and intestinal dysmotility through ACE/FFAR2-mediated modulation of the microbiota-gutbrain axis, with downstream effects including reduced microglial neuroinflammation, restored intestinal and blood-brain barrier integrity, and enhanced colonic serotonin secretion-mechanistic findings subsequently confirmed in BV-2 cell culture models (Xu et al., 2025).Expanding beyond classical gut-brain dyads, several contributions introduce novel axis frameworks with broad clinical implications. Zhang et al. explored the interaction between gut microbiota and anesthesia through the lens of the gut-brain-liver axis, revealing that anesthetic agents reshape microbial composition by disrupting intestinal barrier function, suppressing beneficial bacterial populations, and inducing bile acid metabolism dysregulation-changes that in turn impair hepatic drug-metabolizing enzyme activity and sustain neuroinflammatory cycles with direct perioperative safety consequences (Zhang et al., 2025). Song et al. proposed a brain-gut-prostate axis in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), integrating microbiome-derived metabolite signaling (including SCFAs and thyrotropinreleasing hormone), neuroendocrine pathways, and Th17/Treg immune imbalance to construct a theoretical framework that transcends conventional localized anti-inflammatory approaches and offers multi-dimensional therapeutic strategies for this clinically refractory condition (Song et al., 2025). Zhai et al. examined Drug-induced brain injury (DIBI) through the gut-brain axis, demonstrating that antibiotic, antineoplastic, and psychoactive drug exposures promote microbial dysbiosis, bacterial translocation, and systemic inflammation that ultimately compromise blood-brain barrier...
- Open Access
- 7 August 2026
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 17, 1865685
Human papillomavirus infection and atherosclerotic cardiovascular disease: a comprehensive review of epidemiological evidence, molecular mechanisms, and vaccination-mediated protection
Emerging epidemiological evidence indicates that persistent infection with high-risk human papillomavirus (HPV) genotypes is independently associated with elevated atherosclerotic cardiovascular disease (CVD) risk, challenging traditional paradigms of cardiovascular risk assessment. This review synthesises current observational data on this association, explores the potential inflammatory, immune, and metabolic mechanisms that may connect HPV to atherogenesis, and evaluates the emerging evidence for cardiovascular protection conferred by HPV vaccination. Large cohort studies report significantly elevated risks of myocardial infarction, stroke, and cardiovascular mortality among women with high-risk HPV infection, independent of conventional risk factors. Mechanistically, HPV oncoproteins E6 and E7 activate nuclear factor-κB (NF-κB)-mediated inflammatory cascades, induce endothelial dysfunction through p53 degradation, and establish a pro-atherogenic systemic inflammatory milieu characterized by elevated interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). Preliminary retrospective analyses further indicate that HPV vaccination is linked to a reduced incidence of new-onset cardiovascular and cerebrovascular events, although healthy-user bias and residual confounding limit causal interpretation. Despite these intriguing signals, the bulk of evidence is derived from cross-sectional and retrospective designs, and the direct demonstration of a causal link remains absent. We discuss critical methodological challenges—including confounding by sexual behaviour, socioeconomic status, and co-infections—and outline a roadmap for prospective cohort studies, mechanistic investigations, and rigorous risk-stratification research. Clarifying the nature of the HPV–CVD relationship could open novel avenues for the primary prevention of atherosclerotic disease through vaccination programmes.
- 7 August 2026
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 17, 1865685
Open AccessHuman papillomavirus infection and atherosclerotic cardiovascular disease: a comprehensive review of epidemiological evidence, molecular mechanisms, and vaccination-mediated protection
Emerging epidemiological evidence indicates that persistent infection with high-risk human papillomavirus (HPV) genotypes is independently associated with elevated atherosclerotic cardiovascular disease (CVD) risk, challenging traditional paradigms of cardiovascular risk assessment. This review synthesises current observational data on this association, explores the potential inflammatory, immune, and metabolic mechanisms that may connect HPV to atherogenesis, and evaluates the emerging evidence for cardiovascular protection conferred by HPV vaccination. Large cohort studies report significantly elevated risks of myocardial infarction, stroke, and cardiovascular mortality among women with high-risk HPV infection, independent of conventional risk factors. Mechanistically, HPV oncoproteins E6 and E7 activate nuclear factor-κB (NF-κB)-mediated inflammatory cascades, induce endothelial dysfunction through p53 degradation, and establish a pro-atherogenic systemic inflammatory milieu characterized by elevated interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). Preliminary retrospective analyses further indicate that HPV vaccination is linked to a reduced incidence of new-onset cardiovascular and cerebrovascular events, although healthy-user bias and residual confounding limit causal interpretation. Despite these intriguing signals, the bulk of evidence is derived from cross-sectional and retrospective designs, and the direct demonstration of a causal link remains absent. We discuss critical methodological challenges—including confounding by sexual behaviour, socioeconomic status, and co-infections—and outline a roadmap for prospective cohort studies, mechanistic investigations, and rigorous risk-stratification research. Clarifying the nature of the HPV–CVD relationship could open novel avenues for the primary prevention of atherosclerotic disease through vaccination programmes.
- Open Access
- 29 July 2026
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 17, 1871025
Therapeutic resistance in HPV-positive oropharyngeal squamous cell carcinoma: molecular mechanisms, clinical challenges, and precision strategies
Human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) exhibits exceptional sensitivity to chemoradiotherapy, with 5-year overall survival exceeding 80%, thereby providing a compelling rationale for treatment de-escalation. However, 15%–20% of patients develop therapeutic resistance and locoregional recurrence, resulting in markedly inferior outcomes. This Review systematically dissects the molecular architecture of treatment resistance in HPV-positive OPSCC, with particular emphasis on mechanisms conferring resistance to radiotherapy, platinum-based chemotherapy, and EGFR-targeted therapy (cetuximab). We delineate core drivers — aberrant DNA damage response (DDR) signaling, epigenetic reprogramming, cancer stem cell (CSC) plasticity, and non-coding RNA networks—and pinpoint actionable vulnerabilities. The contributions and limitations of patient-derived organoids, genetically engineered mouse models, and pivotal clinical trials (notably RTOG 1016) are critically appraised. We address persistent controversies, including the complex relationship between de-escalation and resistance, and highlight the lack of integrative resistance biomarkers. Finally, we propose a roadmap to bridge translational gaps and accelerate the development of precision strategies that circumvent resistance.
- 29 July 2026
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 17, 1871025
Open AccessTherapeutic resistance in HPV-positive oropharyngeal squamous cell carcinoma: molecular mechanisms, clinical challenges, and precision strategies
Human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) exhibits exceptional sensitivity to chemoradiotherapy, with 5-year overall survival exceeding 80%, thereby providing a compelling rationale for treatment de-escalation. However, 15%–20% of patients develop therapeutic resistance and locoregional recurrence, resulting in markedly inferior outcomes. This Review systematically dissects the molecular architecture of treatment resistance in HPV-positive OPSCC, with particular emphasis on mechanisms conferring resistance to radiotherapy, platinum-based chemotherapy, and EGFR-targeted therapy (cetuximab). We delineate core drivers — aberrant DNA damage response (DDR) signaling, epigenetic reprogramming, cancer stem cell (CSC) plasticity, and non-coding RNA networks—and pinpoint actionable vulnerabilities. The contributions and limitations of patient-derived organoids, genetically engineered mouse models, and pivotal clinical trials (notably RTOG 1016) are critically appraised. We address persistent controversies, including the complex relationship between de-escalation and resistance, and highlight the lack of integrative resistance biomarkers. Finally, we propose a roadmap to bridge translational gaps and accelerate the development of precision strategies that circumvent resistance.
- Open Access
- 11 August 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1)
Exo-hydrogel therapy: a revolutionary approach to managing diabetic complications
The online version contains supplementary material available at 10.1186/s12951-025-03621-6. The online version contains supplementary material available at 10.1186/s12951-025-03621-6.
- 11 August 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1)
Open AccessExo-hydrogel therapy: a revolutionary approach to managing diabetic complications
The online version contains supplementary material available at 10.1186/s12951-025-03621-6. The online version contains supplementary material available at 10.1186/s12951-025-03621-6.
- 1 October 2024
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 24 (12) , 1395-1409
Fasting: A Complex, Double-Edged Blade in the Battle Against Doxorubicin-Induced Cardiotoxicity
In recent years, there has been a surge in the popularity of fasting as a method to enhance one’s health and overall well-being. Fasting is a customary practice characterized by voluntary refraining from consuming food and beverages for a specified duration, ranging from a few hours to several days. The potential advantages of fasting, including enhanced insulin sensitivity, decreased inflammation, and better cellular repair mechanisms, have been well documented. However, the effects of fasting on cancer therapy have been the focus of recent scholarly investigations. Doxorubicin (Dox) is one of the most widely used chemotherapy medications for cancer treatment. Unfortunately, cardiotoxicity, which may lead to heart failure and other cardiovascular issues, has been linked to Dox usage. This study aims to comprehensively examine the possible advantages and disadvantages of fasting concerning Dox-induced cardiotoxicity. Researchers have investigated the potential benefits of fasting in lowering the risk of Dox-induced cardiac damage to solve this problem. Nevertheless, new studies indicate that prolonged alternate-day fasting may adversely affect the heart’s capacity to manage the cardiotoxic properties of Dox. Though fasting may benefit overall health, it is essential to proceed cautiously and consider the potential risks in certain circumstances.
- 1 October 2024
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 24 (12) , 1395-1409
Fasting: A Complex, Double-Edged Blade in the Battle Against Doxorubicin-Induced Cardiotoxicity
In recent years, there has been a surge in the popularity of fasting as a method to enhance one’s health and overall well-being. Fasting is a customary practice characterized by voluntary refraining from consuming food and beverages for a specified duration, ranging from a few hours to several days. The potential advantages of fasting, including enhanced insulin sensitivity, decreased inflammation, and better cellular repair mechanisms, have been well documented. However, the effects of fasting on cancer therapy have been the focus of recent scholarly investigations. Doxorubicin (Dox) is one of the most widely used chemotherapy medications for cancer treatment. Unfortunately, cardiotoxicity, which may lead to heart failure and other cardiovascular issues, has been linked to Dox usage. This study aims to comprehensively examine the possible advantages and disadvantages of fasting concerning Dox-induced cardiotoxicity. Researchers have investigated the potential benefits of fasting in lowering the risk of Dox-induced cardiac damage to solve this problem. Nevertheless, new studies indicate that prolonged alternate-day fasting may adversely affect the heart’s capacity to manage the cardiotoxic properties of Dox. Though fasting may benefit overall health, it is essential to proceed cautiously and consider the potential risks in certain circumstances.
- Open Access
- 9 August 2024
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 137 (18) , 2169-2181
Bacterial outer membrane vesicles in the fight against cancer
Bacterial outer membrane vesicles (OMVs) are diminutive vesicles naturally released by Gram-negative bacteria. These vesicles possess distinctive characteristics that attract attention for their potential use in drug administration and immunotherapy in cancer treatment. Therapeutic medicines may be delivered via OMVs directly to the tumor sites, thereby minimizing exposure to healthy cells and lowering the risk of systemic toxicity. Furthermore, the activation of the immune system by OMVs has been demonstrated to facilitate the recognition and elimination of cancer cells, which makes them a desirable tool for immunotherapy. They can also be genetically modified to carry specific antigens, immunomodulatory compounds, and small interfering RNAs, enhancing the immune response to cancerous cells and silencing genes associated with disease progression. Combining OMVs with other cancer treatments like chemotherapy and radiation has shown promising synergistic effects. This review highlights the crucial role of bacterial OMVs in cancer, emphasizing their potential as vectors for novel cancer targeted therapies. As researchers delve deeper into the complexities of these vesicles and their interactions with tumors, there is a growing sense of optimism that this avenue of study will bring positive outcomes and renewed hope to cancer patients in the foreseeable future.
- 9 August 2024
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 137 (18) , 2169-2181
Open AccessBacterial outer membrane vesicles in the fight against cancer
Bacterial outer membrane vesicles (OMVs) are diminutive vesicles naturally released by Gram-negative bacteria. These vesicles possess distinctive characteristics that attract attention for their potential use in drug administration and immunotherapy in cancer treatment. Therapeutic medicines may be delivered via OMVs directly to the tumor sites, thereby minimizing exposure to healthy cells and lowering the risk of systemic toxicity. Furthermore, the activation of the immune system by OMVs has been demonstrated to facilitate the recognition and elimination of cancer cells, which makes them a desirable tool for immunotherapy. They can also be genetically modified to carry specific antigens, immunomodulatory compounds, and small interfering RNAs, enhancing the immune response to cancerous cells and silencing genes associated with disease progression. Combining OMVs with other cancer treatments like chemotherapy and radiation has shown promising synergistic effects. This review highlights the crucial role of bacterial OMVs in cancer, emphasizing their potential as vectors for novel cancer targeted therapies. As researchers delve deeper into the complexities of these vesicles and their interactions with tumors, there is a growing sense of optimism that this avenue of study will bring positive outcomes and renewed hope to cancer patients in the foreseeable future.
- 4 June 2024
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 200, 104403
A viable remedy for overcoming resistance to anti-PD-1 immunotherapy: Fecal microbiota transplantation
- 4 June 2024
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 200, 104403
A viable remedy for overcoming resistance to anti-PD-1 immunotherapy: Fecal microbiota transplantation
- Top Cited PapersOpen Access
- 22 March 2024
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 14, 1280636
Vaginal microbiota transplantation is a truly opulent and promising edge: fully grasp its potential
Vaginal microbiota transplantation (VMT) is a cutting-edge treatment modality that has the potential to revolutionize the management of vaginal disorders. The human vagina is a complex and dynamic ecosystem home to a diverse community of microorganisms. These microorganisms play a crucial role in maintaining the health and well-being of the female reproductive system. However, when the balance of this ecosystem is disrupted, it can lead to the development of various vaginal disorders. Conventional treatments, such as antibiotics and antifungal medications, can temporarily relieve the symptoms of vaginal disorders. However, they often fail to address the underlying cause of the problem, which is the disruption of the vaginal microbiota. In recent years, VMT has emerged as a promising therapeutic approach that aims to restore the balance of the vaginal ecosystem. Several studies have demonstrated the safety and efficacy of VMT in treating bacterial vaginosis, recurrent yeast infections, and other vaginal conditions. The procedure has also shown promising results in reducing the risk of sexually transmitted infections and preterm birth in pregnant women. However, more research is needed to establish optimal donor selection, preparation, and screening protocols, as well as long-term safety and efficacy. VMT offers a safe, effective, and minimally invasive treatment option for women with persistent vaginal problems. It could improve the quality of life for millions of women worldwide and become a standard treatment option shortly. With further research and development, it could potentially treat a wide range of other health problems beyond the scope of vaginal disorders.
- 22 March 2024
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 14, 1280636
Top Cited PapersOpen AccessVaginal microbiota transplantation is a truly opulent and promising edge: fully grasp its potential
Vaginal microbiota transplantation (VMT) is a cutting-edge treatment modality that has the potential to revolutionize the management of vaginal disorders. The human vagina is a complex and dynamic ecosystem home to a diverse community of microorganisms. These microorganisms play a crucial role in maintaining the health and well-being of the female reproductive system. However, when the balance of this ecosystem is disrupted, it can lead to the development of various vaginal disorders. Conventional treatments, such as antibiotics and antifungal medications, can temporarily relieve the symptoms of vaginal disorders. However, they often fail to address the underlying cause of the problem, which is the disruption of the vaginal microbiota. In recent years, VMT has emerged as a promising therapeutic approach that aims to restore the balance of the vaginal ecosystem. Several studies have demonstrated the safety and efficacy of VMT in treating bacterial vaginosis, recurrent yeast infections, and other vaginal conditions. The procedure has also shown promising results in reducing the risk of sexually transmitted infections and preterm birth in pregnant women. However, more research is needed to establish optimal donor selection, preparation, and screening protocols, as well as long-term safety and efficacy. VMT offers a safe, effective, and minimally invasive treatment option for women with persistent vaginal problems. It could improve the quality of life for millions of women worldwide and become a standard treatment option shortly. With further research and development, it could potentially treat a wide range of other health problems beyond the scope of vaginal disorders.
- 1 March 2024
- Published by Wiley in Physiologia Plantarum
- Vol. 176 (2) , e14283
Plant‐derived nanovesicles offer a promising avenue for anti‐aging interventions
Over the past few years, the study of plant‐derived nanovesicles (PDNVs) has emerged as a hot topic of discussion and research in the scientific community. This remarkable interest stems from their potential role in facilitating intercellular communication and their unique ability to deliver biologically active components, including proteins, lipids, and miRNAs, to recipient cells. This fascinating ability to act as a molecular courier has opened up an entirely new dimension in our understanding of plant biology. The field of research focusing on the potential applications of PDNVs is still in its nascent stages. However, it has already started gaining traction due to the growing interest in its possible use in various branches of biotechnology and medicine. Their unique properties and versatile applications offer promising future research and development prospects in these fields. Despite the significant progress in our understanding, many unanswered questions and mysteries surround the mechanisms by which PDNVs function and their potential applications. There is a dire need for further extensive research to elucidate these mechanisms and explore the full potential of these fascinating vesicles. As the technology at our disposal advances and our understanding of PDNVs deepens, it is beyond doubt that PDNVs will continue to be a subject of intense research in anti‐aging therapeutics. This comprehensive review is designed to delve into the fascinating and multifaceted world of PDNV‐based research, particularly focusing on how these nanovesicles can be applied to anti‐aging therapeutics.
- 1 March 2024
- Published by Wiley in Physiologia Plantarum
- Vol. 176 (2) , e14283
Plant‐derived nanovesicles offer a promising avenue for anti‐aging interventions
Over the past few years, the study of plant‐derived nanovesicles (PDNVs) has emerged as a hot topic of discussion and research in the scientific community. This remarkable interest stems from their potential role in facilitating intercellular communication and their unique ability to deliver biologically active components, including proteins, lipids, and miRNAs, to recipient cells. This fascinating ability to act as a molecular courier has opened up an entirely new dimension in our understanding of plant biology. The field of research focusing on the potential applications of PDNVs is still in its nascent stages. However, it has already started gaining traction due to the growing interest in its possible use in various branches of biotechnology and medicine. Their unique properties and versatile applications offer promising future research and development prospects in these fields. Despite the significant progress in our understanding, many unanswered questions and mysteries surround the mechanisms by which PDNVs function and their potential applications. There is a dire need for further extensive research to elucidate these mechanisms and explore the full potential of these fascinating vesicles. As the technology at our disposal advances and our understanding of PDNVs deepens, it is beyond doubt that PDNVs will continue to be a subject of intense research in anti‐aging therapeutics. This comprehensive review is designed to delve into the fascinating and multifaceted world of PDNV‐based research, particularly focusing on how these nanovesicles can be applied to anti‐aging therapeutics.